ACTRN12606000505505终止1 期
A phase Ib dose escalation study of the safety and tolerability of oglufanide disodium (IM862) in patients with chronic hepatitis C virus (HCV) infection
Implicit Bioscience Pty Ltd0 个研究点目标入组 32 人开始时间: 2006年12月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •Serological evidence of hepatitis C infection by anti-HCV antibody test and HCV RNA detectable by PCR; Liver biopsy showing Metavir fibrosis stage = or <2 within 3 or 5 years, for moderate or mild disease respectively; Able to give written informed consent and comply with protocol requirements; Has failed to respond to conventional antiviral therapy, has relapsed, or has declined to receive these drugs (previous ribavirin treatment must be >6 months prior to enrolment).
排除标准
- •Women who are pregnant, breastfeeding or of child-bearing potential who are not using at least two forms of acceptable methods of birth control; Co-infection with HBV or HIV; Patients who are expected to need systemic antiviral therapy at any time during their participation; Renal impairment (creatinine >0.15 mmol/L; Specific enzymes > 5x upper limit of normal, bilirubin> 30umol/L; Haematological abnormalities (Hb <110g/L, lymphocyte count <0.8x10^9/L, platelet count <100x10^9/L); History or evidence of bleeding from oesphageal varices or other conditions consistent with decompensated liver disease; History or evidence of chronic pulmonary disease associated with functional limitations; History of major organ transplantation with an existing functional graft; Haemophilia or any other condition that would preclude liver biopsy; Alcohol intake >30g/day for men or >20g/day for women or evidence of alcohol abuse within 6 months of screening; Poorly controlled diabetes mellitus; Patients taking herbal or antioxidant therapies; Substance abuse with IV or inhaled drugs; Evidence of liver disease due to other disorders (eg. untreated haemochromatosis, alcoholic liver disease, Wilson's disease, autoimmune hepatitis, toxin exposure, alpha1-antitrypsin); Persons currently (or within 3 months prior to enrolment) taking systemic immunosuppressive or immunomodulative medication including interferon (use of topical or inhalant corticosteroids is acceptable); Evidence of ongoing autoimmune disease (clinically manifest vasculitis, ANA titre >640, AMA titre >160, anti smooth muscle antibody titre >160); Acute illness within 72 hours prior to first drug administration; Administration of any investigational drug or vaccine or any registered vaccine within 30 days prior to and during the dosing phase in this study or within 5 half lives of the investigational drug, which ever is shorter; Any medical or social condition that in the opinion of the investigator would interfere with the interpretation or evaluation of the study product; Subjects in whom it is not possible to obtain a pre-dose blood sample without undue trauma or distress; Evidence of an active or suspected cancer or a history of malignancy where the risk of recurrence is >20% within 2 years; Body mass index >36 or <18; Donation or loss of more than 400ml of blood within 2 months prior to anticipated dose administration; History of clinically significant drug allergy; History of a severe seizure disorder or current anticonvulsant use.
研究者
相似试验
已完成
1 期
Study of safety and efficacy of ribociclib and letrozole or fulvestrant or tamoxifen in preand postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancerJPRN-jRCT2080222714ovartis Pharma. K.K.60
招募中
1 期
Effect of briquilimab in patients with patches of itching skin because of chronic spontaneous urticaria (CSU) despite treatment with antihistaminesChronic Spontaneous UrticariaMedDRA version: 20.0Level: PTClassification code: 10072757Term: Chronic spontaneous urticaria Class: 100000004858CTIS2023-505446-25-00Jasper Therapeutics Inc.47
进行中（未招募）
1 期
A study to test if increasing doses of the drug INCB050465 is safe and well tolerated in patients with Pemphigus VulgarisPemphigus vulgarisMedDRA version: 20.0Level: LLTClassification code 10052802Term: Pemphigus vulgarisSystem Organ Class: 100000004858EUCTR2018-002146-37-ITINCYTE CORPORATIO18
进行中（未招募）
1 期
A study to test if increasing doses of the drug INCB050465 is safe and well tolerated in patients with Pemphigus VulgarisPemphigus vulgarisMedDRA version: 20.0 Level: LLT Classification code 10052802 Term: Pemphigus vulgaris System Organ Class: 100000004858EUCTR2018-002146-37-FRIncyte Corporation18
尚未招募
1 期
A Phase 1 Study for patients with advanced solid tumors.CTRI/2011/12/002225Orchid Research Laboratories Ltd36